Sumitomo Mitsui DS Asset Management Company Ltd Increases Position in AbbVie Inc. $ABBV

Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in AbbVie Inc. (NYSE:ABBV) by 1.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 324,551 shares of the company’s stock after purchasing an additional 3,394 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in AbbVie were worth $81,670,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ABBV. Litman Gregory Wealth Management LLC purchased a new position in AbbVie in the fourth quarter valued at about $28,000. Imprint Wealth LLC boosted its stake in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie in the 4th quarter worth approximately $31,000. Finally, WestEnd Advisors LLC grew its holdings in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company lifted their price objective on AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, July 10th. Canaccord Genuity Group upped their target price on AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research report on Thursday. Cantor Fitzgerald lifted their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Finally, Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.50.

AbbVie Stock Down 0.6%

Shares of AbbVie stock opened at $249.20 on Friday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The business’s fifty day moving average is $244.94 and its two-hundred day moving average is $226.12. The firm has a market cap of $440.29 billion, a PE ratio of 70.40, a P/E/G ratio of 0.83 and a beta of 0.30.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie Inc. will post 14.07 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie’s payout ratio is 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV’s Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.